Pediatrics international : official journal of the Japan Pediatric Society 2017 04 22() doi 10.1111/ped.13306
This study measured cell-mediated immunity (CMI) and serum antibody levels to clarify the basis of breakthrough after vaccination and reinfection after mumps.
From a pool of 54 college students, 17 seronegative subjects and 14 subjects with intermediate levels of antibodies against mumps were vaccinated with a monovalent mumps vaccine and CMI was assessed using an interferon-γ release assay.
CMI positivity in subjects classified by pre-existing antibody levels, which gave groups with titers of <2.0 (negative), 2.0~3.9 (intermediate), and ≥4.0 index units (positive), was 8/17 (47.1%), 9/14 (64.3%) and 19/23 (82.6%) before vaccination. Of the 17 seronegative subjects, 7 (41.2%) had a history of vaccination and/or natural infection, 4 (57.1%) of whom had CMI positive or intermediate. Ten (71%) of 14 subjects with intermediate levels had a history of vaccination or natural infection, and 8 (80%) of whom had CMI positive or intermediate. After vaccination the IFN-γ and antibody titers increased significantly, but 7 (41.2%) of the 17 seronegative subjects and 13 (92.9%) of the 14 subjects with intermediate levels tested positive for both antibody and CMI. In a comparison of the natural infection group (confirmed with IgG seropositive and/or CMI positive without vaccination) vs. the vaccination group, the IgG antibody titers (mean ± SD) were 14.4 ± 8.0 vs. 3.6 ± 2.4 index units (p<0.01) and the IFN-γ values were 122.7 ± 90.0 pg/mL vs. 59.5 ± 37.8 pg/mL (p>0.05), respectively.
Vaccination or even natural mumps infection did not always induce both cellular and humoral immunity. This article is protected by copyright. All rights reserved.